(2020). Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
Chicago Style (17th ed.) CitationInhibition of SARS-CoV-2 (previously 2019-nCoV) Infection by a Highly Potent Pan-coronavirus Fusion Inhibitor Targeting Its Spike Protein That Harbors a High Capacity to Mediate Membrane Fusion. 2020.
MLA (8th ed.) CitationInhibition of SARS-CoV-2 (previously 2019-nCoV) Infection by a Highly Potent Pan-coronavirus Fusion Inhibitor Targeting Its Spike Protein That Harbors a High Capacity to Mediate Membrane Fusion. 2020.
Warning: These citations may not always be 100% accurate.